A Washington Post article about scaled-back assessments of the 'modest' success of an HIV vaccine trial in Thailand incorrectly said that the vaccine was 40 to 50 percent effective in people who identified themselves as being at high or medium risk for becoming infected. That was the success rate for those who said they were at low or medium risk. 